Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 4/20 | 0.32 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7634046 | 0.82 | TRPA1 (0.39) | TRPA1TRPM8EPHX2GABRR1GABRR2 | |
| SCHEMBL20124552 | 0.80 | CA1 (0.36) | GABRR1GABRR2CA1CA2CA4 | |
| SCHEMBL18644147 | 0.79 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL3249131 | 0.79 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL27732658 | 0.79 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL31516173 | 0.79 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL3479883 | 0.79 | TRPA1 (0.45) | TRPA1TRPM8EPHX2CA1CA2 | |
| SCHEMBL12159671 | 0.79 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL12077578 | 0.78 | TRPA1 (0.33) | TRPA1TRPM8EPHX2GABRR1GABRR2 | |
| SCHEMBL3537569 | 0.78 | EPHX2 (0.33) | EPHX2GABRR1GABRR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325932-A1 | 4-PIPERIDYLBENZAMIDES AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC | 2009-12-31 | — | — | US | disclosed |
| EP-0866055-B1 | Pocess for the preparation of 1-amino-1-methyl-3(4)-aminomethylcyclohexane | BAYER AG (DE) | 2002-07-03 | — | — | EP | disclosed |
| US-5905170-A | SIMULTANEOUSLY REACTING 4(5)-AMINOEMTHYL-1-METHYLCYCLOHEXANE, HYDROCYANIC ACID AND AQUEOUS SULFURIC ACID TO FORM 1-FORMAMIDO-1-METHYL-3(4)-AMINOMETHYLCYCLOHEXANE, HYDROLYZING THE FORMAMIDE AND HYDROCYANIC ACID, ADDING A BASE | BAYER AKTIENGESELLSCHAFT (DE) | 1999-05-18 | — | — | US | disclosed |
| EP-0866055-A2 | Pocess for the preparation of 1-amino-1-mentyl-3(4)-aminomethylcyclohexane | BAYER AG (DE) | 1998-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325932-A1 | 4-PIPERIDYLBENZAMIDES AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | HSD11B1, HSD3B1, HSD17B1 | TRPA1 4362/4885TRPM8 4674/4885EPHX2 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.